News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Peplin Inc. Files to Withdraw IPO Plans
June 10, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, June 9 (Reuters) - Peplin Inc on Monday filed with regulators to withdraw its plan for a $75 million initial public offering, citing unfavorable market conditions.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Obesity
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
December 9, 2025
·
2 min read
·
Dan Samorodnitsky
Venture capital
Lilly, Novo GLP-1 Pricing Plans Clear Runway For Future Competitors
December 3, 2025
·
2 min read
·
Annalee Armstrong
Gene editing
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
December 1, 2025
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Avidity Played Hardball To Land Favorable Terms in $12B Novartis Deal
November 25, 2025
·
3 min read
·
Annalee Armstrong
